Drug-screening

药物筛选
  • 文章类型: Journal Article
    在过去的十年里,肠道类器官技术为体外复制肠道生理过程中的组织或器官形态发生以及研究各种肠道疾病的发病机理铺平了道路。肠道类器官在药物筛选中受到青睐,因为它们具有高通量体外培养的能力,并且与患者的遗传特征更相似。此外,作为疾病模型,肠道类器官在筛选诊断标志物方面有广泛的应用,确定治疗目标,探索疾病的表观遗传机制。此外,作为一个可移植的细胞系统,在溃疡性结肠炎和短肠综合征等疾病中,类器官在受损上皮的重建中发挥了重要作用,以及肠道物质交换和代谢功能恢复。跨学科方法的兴起,包括类器官芯片技术,基因组编辑技术,和微流体,大大加速了类器官的发展。在这次审查中,首先使用VOSviewer软件可视化肠道类器官的热合被引期刊和关键词趋势。随后,我们总结了目前肠道类器官技术在疾病建模中的应用,药物筛选,和再生医学。这将加深我们对肠道类器官的理解,并进一步探索肠道的生理机制和肠道疾病的药物开发。
    In the past decade, intestinal organoid technology has paved the way for reproducing tissue or organ morphogenesis during intestinal physiological processes in vitro and studying the pathogenesis of various intestinal diseases. Intestinal organoids are favored in drug screening due to their ability for high-throughput in vitro cultivation and their closer resemblance to patient genetic characteristics. Furthermore, as disease models, intestinal organoids find wide applications in screening diagnostic markers, identifying therapeutic targets, and exploring epigenetic mechanisms of diseases. Additionally, as a transplantable cellular system, organoids have played a significant role in the reconstruction of damaged epithelium in conditions such as ulcerative colitis and short bowel syndrome, as well as in intestinal material exchange and metabolic function restoration. The rise of interdisciplinary approaches, including organoid-on-chip technology, genome editing techniques, and microfluidics, has greatly accelerated the development of organoids. In this review, VOSviewer software is used to visualize hot co-cited journal and keywords trends of intestinal organoid firstly. Subsequently, we have summarized the current applications of intestinal organoid technology in disease modeling, drug screening, and regenerative medicine. This will deepen our understanding of intestinal organoids and further explore the physiological mechanisms of the intestine and drug development for intestinal diseases.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    一种严重的肺炎,被世界卫生组织命名为2019年冠状病毒病(COVID-19),在中国爆发并迅速发展成为全球大流行,全球报告了数百万例病例和数十万例死亡病例。新型冠状病毒,被指定为严重急性呼吸道综合症冠状病毒2(SARS-CoV-2),被确定为COVID-19的病原体。根据以往SARS-CoV和MERS-CoV爆发和研究积累的经验,一系列研究迅速进行,在理解SARS-CoV-2的系统发育和基因组组织以及其感染和复制的分子机制方面取得了重大进展。在本次审查中,我们总结了在阐明SARS-CoV-2关键蛋白的结构和功能方面的重要进展,尤其是主要的蛋白酶,RNA依赖性RNA聚合酶,刺突糖蛋白,和核衣壳蛋白。有关其相关抑制剂和药物的研究结果也得到了强调。
    A severe form of pneumonia, named coronavirus disease 2019 (COVID-19) by the World Health Organization, broke out in China and rapidly developed into a global pandemic, with millions of cases and hundreds of thousands of deaths reported globally. The novel coronavirus, which was designated as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was identified as the etiological agent of COVID-19. On the basis of experience accumulated following previous SARS-CoV and MERS-CoV outbreaks and research, a series of studies have been conducted rapidly, and major progress has been achieved with regard to the understanding of the phylogeny and genomic organization of SARS-CoV-2 in addition its molecular mechanisms of infection and replication. In the present review, we summarized crucial developments in the elucidation of the structure and function of key SARS-CoV-2 proteins, especially the main protease, RNA-dependent RNA polymerase, spike glycoprotein, and nucleocapsid protein. Results of studies on their associated inhibitors and drugs have also been highlighted.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

       PDF(Pubmed)

公众号